Coca-Cola Consolidated Inc
Change company Symbol lookup
Select an option...
COKE Coca-Cola Consolidated Inc
KALU Kaiser Aluminum Corp
SEED Origin Agritech Ltd
DFFN Diffusion Pharmaceuticals Inc
PCSB PCSB Financial Corp
BHB Bar Harbor Bankshares
EH Ehang Holdings Ltd
CNSL Consolidated Communications Holdings Inc
WLFC Willis Lease Finance Corp
HCI Hci Group Inc

Consumer Staples : Beverages | Small Cap Growth
Company profile

Coca-Cola Consolidated Inc, formerly Coca-Cola Bottling Co. Consolidated, produces, markets and distributes nonalcoholic beverages. The Company is an independent Coca-Cola bottler in the United States. The Company's segments include Nonalcoholic Beverages and All Other. Majority of its total bottle/can volume to retail customers consist of products of The Coca-Cola Company. It also distributes products for various other beverage brands, including Dr Pepper, Sundrop and Monster Energy. The Company's product offerings include both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca-Cola. Still beverages include energy products and noncarbonated beverages, such as bottled water, tea, ready to drink coffee, enhanced water, juices and sports drinks. There are two main categories of sales, which include bottle/can sales and other sales.

Closing Price
Day's Change
23.16 (10.07%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:

UPDATE: Cannabis stocks pare early gains as profit doubts persist a day after major selloff

7:02 am ET October 14, 2019 (MarketWatch)

By Ciara Linnane, MarketWatch

Jefferies downgrades Canopy Growth and cuts share-price targets on the sector by an average 50%

Cannabis stocks surrendered some of their early gains Friday, as the concerns about a lack of profits in the sector that sparked a massive re-rating of risk this week (, putting the sector on track for double-digits losses on the week.

The rout was triggered by a revenue warning from Hexo Corp ( (HEXO.T)that served as a reminder to investors that the much-hoped-for sales gains and profitability that sent stocks to record highs earlier this year are not materializing.

The news came near the conclusion of a week in which the continued power of the black market was in focus, after Statistics Canada ( released crowdsourced price data for the black and legal markets and found an average legal price in the third quarter of C$10.23 a gram, almost double the black-market average price of C$5.59 a gram.

There was further bad news when a major deal involving retailer MedMen ( through, Aleafia Health (ALEF.T)dropped Aphria(APHA.T) (APHA.T)as a supplier and Green Organic Dutchman (TGOD.T)highlighted the difficulty in accessing capital at viable prices. Hexo closed down 23% and sent a swath of stocks down by a double-digit percentage.

"We call this the 'sanitation cycle,' " said Korey Bauer, portfolio manager at the Cannabis Growth mutual fundfrom Foothill Management. "This is what happens with a new sector. We're going through a phase now where the companies that are doing the right things -- not overspending, hunkering down -- will survive, and the ones that don't will not."

The cannabis sector is still mostly driven by retail investors, he said, with little institutional money in play because of the U.S.'s federal ban on cannabis. Retail investors can be more skittish when signs of trouble emerge, such as the lung disease (, which has sickened more than 1,200 Americans and killed at least 26, that is understood to be caused by vaping, albeit of black-market products.

"Illegal vapes are the problem, and that should be good for legal companies," Bauer said.

Investors are disappointed by the experience of the legal-cannabis rollout in Canada, which is coming up on its one-year anniversary. Companies continue to express frustration at how few stores have been approved and opened, causing would-be customers to continue to tap the black market.

Read:Aurora Cannabis earnings: When does pot profit actually arrive? (

Related:Canopy Growth slides 14% to drag broader cannabis sector lower as earnings disappoint (

In case you missed it: Cannabis companies are having a horrible summer as scandals mount and stocks slide (

Ontario currently has about 75 stores, and needs 1,400 if it wants to match Colorado's ratio of stores to 10,000 inhabitants. "Access to the legal market is huge," said Bauer.

The next phase will likely be defaults, pushing some companies into bankruptcy. But that's a good thing, he added, because right now there are too many companies, too much supply and not enough outlets to sell it.

"There's a select group of stocks that are now trading at fair value or below relative to where they were six months ago," he said. "We're taking advantage of the dislocation, but we think they will make it out, while the rest get left behind. We have moved from caring about revenue to positive EBITDA to just, 'Will you still be in business this time next year?' incredibly quickly."

Jefferies downgraded market leader Canopy Growth(WEED.T) (WEED.T)and cut its share-price targets on cannabis stocks by an average of 50% to reflect the greater risk and volatility in the sector. Analysts Owen Bennett and Ryan Tomkins agreed that the next 12 months will "see strong divergence between those who can execute/move to profit and the rest."

The analysts upgraded Flowr Corp.(FLWR.V), Hexo and Organigram(OGI.T)and named Aurora Cannabis(ACB.T)(ACB.T), Green Organic Dutchman and Aphria as top picks in the sector, with buy ratings.

Canopy is "the most expensive name across the space (even with recent sell off) and although it continues to have material potential long-term, signs of share pressures in Canada, near term weak GM (gross margin)/profit performance (especially vs. its closest peers), lack of material catalysts, and question marks over how successful beverages will be see us move to underperform."

GMP analyst Robert Fagan downgraded Hexo to hold from buy and slashed his stock-price target to C$4 ($3) from C$9.50. MKM analyst Bill Kirk stuck with his buy rating on the stock, but lowered his price target to C$7 from C$12.

Hexo shares were down 6.7%. Canopy fell 4%. Valens GroWorkwas down 3.3%.

But Cronos gave up early gains to trade down 0.6%. Tilray(TLRY)rose 0.9%, Aurora Cannabis fell 1.6% and Aleafia Health down 0.2%. Aphria rose 2.7%, Organigram was up 9.5% and Green Organic Dutchman rallied 45.

The ETFMG Alternative Harvest ETF(MJ)was up 0.1%, well off its early highs with 26 of its 38 constituent stocks trading higher. The Horizons Marijuana Life Sciences ETFturned down 1.6%, with 25 of its 54 components trading higher. The former has lost 11% on the week, while the latter is down 14%.

The S&P 500and the Dow Jones Industrial Averagewere up 1.5%.

Cannabis Watch:Read all of MarketWatch's coverage of cannabis stocks (

-Ciara Linnane; 415-439-6400;

(END) Dow Jones Newswires

October 14, 2019 07:02 ET (11:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.